VEEVA SYSTEMS INC
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Veeva Systems (VEEV) reports over 175 biotech firms using its Veeva Basics platform. The platform helps startups establish tech infrastructure for clinical, regulatory, and commercial operations. Companies like Whitehawk and Structure Therapeutics cite efficiency gains. Veeva serves 1,500 life sciences customers and will host an R&D and Quality Summit in October.
Veeva Systems (VEEV) announced its Data Quality System has processed data for 1 million clinical trial subjects, reducing reconciliation time. The system automates workflows and uses AI for data classification. VEEV will discuss Study Builder Agent at its R&D and Quality Summit. The company serves over 1,500 life sciences customers.
Rizzo Daniel J (EVP, Sales, Consulting, & Svcs) sold 4,841 shares of VEEVA SYSTEMS INC (VEEV) at an average of $276.51 ($276.21–$276.53, $1.34M total) across 2 trades on 2026-10-02.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning VEEV (VEEVA SYSTEMS INC). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent VEEV coverage spans technology, financial news and insider activity.
In the last 30 days, VEEV insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($1.6M). The most active reporter was Rizzo Daniel J, EVP, Sales, Consulting, & Svcs, with 2 filings. 33% of those filings were made under pre-arranged Rule 10b5-1 plans.
The adoption announcement could lift Veeva's stock as investors view it as a sign of expanding addressable market and recurring revenue growth.
The announcement highlights Veeva's expanding data capabilities, which may improve its competitive position in the life‑sciences SaaS market.
The insider sale may create modest downward pressure on VEEV as investors price the sell‑off.
Competitive win reduces risk perception.
Potential modest selling pressure on VEEV.
AlphAI scores every news story that mentions VEEV with an AI model for sentiment and relevance, and aggregates insider trades from VEEVA SYSTEMS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Veeva Systems (VEEV) reports over 175 biotech firms using its Veeva Basics platform. The platform helps startups establish tech infrastructure for clinical, regulatory, and commercial operations. Companies like Whitehawk and Structure Therapeutics cite efficiency gains. Veeva serves 1,500 life sciences customers and will host an R&D and Quality Summit in October.
1 min readVeeva Systems (VEEV) announced its Data Quality System has processed data for 1 million clinical trial subjects, reducing reconciliation time. The system automates workflows and uses AI for data classification. VEEV will discuss Study Builder Agent at its R&D and Quality Summit. The company serves over 1,500 life sciences customers.
1 min readRizzo Daniel J (EVP, Sales, Consulting, & Svcs) sold 4,841 shares of VEEVA SYSTEMS INC (VEEV) at an average of $276.51 ($276.21–$276.53, $1.34M total) across 2 trades on 2026-10-02.
1 min readWells Fargo named 13 stocks across seven sectors for its 4Q 2026 long ideas, all rated 'overweight' with expected 10%+ returns. Key picks include Roblox (bookings guidance $2.01B-$2.07B), Occidental Petroleum, and Microsoft. Price targets and catalysts are provided for each.
3 min readVeeva Systems officer Daniel Rizzo filed a notice to sell 4,841 shares, valued at $1.34M, acquired from restricted stock vesting between 2020 and 2026. The sale is planned for October 2, 2026, with 161.9M shares outstanding.
1 min readJim Cramer highlighted the strong performance of enterprise software stocks in Q3, including Salesforce (CRM, +46%), Veeva (VEEV, +60%), and Palantir (PLTR, +60%), despite earlier AI-driven sell-offs. He attributed the rebound to investor confidence in AI-driven growth and noted potential upside for Microsoft (MSFT, +37%). Cramer also discussed Cybersecurity stock CrowdStrike (CRWD, +39%) and AI-related stock Corning (GLW, -40%).
2 min readVeeva Systems (NYSE:VEEV) launched Falcon Router, an AI-powered tool for automating safety and medical communications in life sciences. The product is part of the Falcon Agent Suite and is designed to integrate with existing workflows. Early adopter programs are planned for January 2027, which could indicate broader adoption and recurring revenue potential.
2 min readVeeva Systems (VEEV) disclosed EVP Daniel J. Rizzo's shareholdings in a Form 3 filing. Rizzo holds 11,688 Class A shares, stock options with exercise prices ranging from $154.00 to $275.82, and restricted stock units (RSUs) vesting between 2026 and 2030. The filing details existing equity awards, not new transactions.
1 min readVeeva Systems VEEV announced a global rollout of its Vault CRM with Amgen AMGN, extending a decade-long partnership. The deal supports Amgen's commercial operations and reinforces Veeva's commercial business, which recently reported its best CRM quarter. Veeva's stock has gained 16.8% year-to-date, outperforming its industry and the S&P 500.
2 min readVeeva Systems (VEEV) launched Falcon Router, an AI agent to automate triage and routing of safety reports, quality complaints, and medical inquiries for biopharmas. It will initially support email and web intake, integrating with Veeva's existing platforms. The product is set for early adopter availability in January 2027. According to the company, the tool aims to improve efficiency and patient focus. Veeva serves over 1,500 life sciences customers.
1 min read
